Interleukin-6 (il-6)/signal transducer and activator of transcription 3 (stat3) pathway inhibitors for use in the treatment of granulomatous diseases
AssigneeUCL Business PLC
InventorsAlan David SALAMA, Scott Russell HENDERSON
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment of granulomatous diseases, and in particular the use of niclosamide, an IL-6 inhibitor, a STAT3 inhibitor, and/or an IL-6/STAT3 pathway inhibitor, in the treatment of a granulomatous disease.
Claims22
An interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) pathway inhibitor for use in treating a granulomatous disease in a subject.
A method of treating a granulomatous disease in subject comprising administering an IL-6/STAT3 pathway inhibitor to the subject.
Niclosamide or a salt thereof for use in treating a granulomatous disease in a subject.
A method of treating a granulomatous disease in subject comprising administering niclosamide or a salt thereof to the subject.
An anti-IL-6 antibody or fragment thereof for use in treating a granulomatous disease in a subject.
A method of treating a granulomatous disease in subject comprising administering an anti-IL-6 antibody or fragment thereof to the subject.
Dependencies are inferred from the claim text.